FGF7 and graft versus host disease: However, administration of palifermin, a recombinant human KGF, did not reduce GVHD incidence or improve overall survival in allo-transplant patients in two randomized controlled trials171,172, although it did reduce mucositis incidence and severity in a subgroup of patients171.